(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 23.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.27%.
Mirum Pharmaceuticals's revenue in 2026 is $471,794,000.On average, 12 Wall Street analysts forecast MIRM's revenue for 2026 to be $33,463,897,839, with the lowest MIRM revenue forecast at $29,161,741,759, and the highest MIRM revenue forecast at $35,594,675,417. On average, 11 Wall Street analysts forecast MIRM's revenue for 2027 to be $40,112,170,571, with the lowest MIRM revenue forecast at $35,743,716,781, and the highest MIRM revenue forecast at $45,491,022,026.
In 2028, MIRM is forecast to generate $44,536,643,357 in revenue, with the lowest revenue forecast at $38,013,257,009 and the highest revenue forecast at $50,779,420,791.